National Health (Pharmaceutical Benefits Scheme- class of pharmaceutical items – Subsection 99ACA(3) Determination 2017

The Determination deploys a small set of legal and administrative concepts. Each is named, defined or invoked within the instrument and is necessary to determine the scope and effect of the measure.

• Determination under subsection 99ACA(3): The instrument states at s 4 that it is made under subsection 99ACA(3) of the National Health Act 1953. The Determination therefore sits within the statutory architecture of the Act and is an exercise of a power conferred by that subsection. The text itself does not reproduce subsection 99ACA(3), so the legal limits and procedural content of that subsection must be ascertained from the Act, but the instrument records that the exercise of power occurred.

• Administrative price reduction: The instrument defines this explicitly at s 5 as "a non‑statutory price reduction that has been agreed under section 85AD of the Act." Two points follow from that definition alone. First, the reduction is characterised as non‑statutory, meaning the Determination treats the reduction as an administrative agreement rather than a statutory rate set directly by primary legislation in this instrument. Second, the reduction is tied to an agreement under section 85AD, so the mechanism for establishing the reduced price is identified by reference to that provision of the Act.

• Class of pharmaceutical items: Section 6 and the Schedule operate together to identify the class. The class is defined by discrete pairings of "listed component drug" and "manner of administration." The Schedule provides a line item list of listed component drugs and the exact manner of administration for each item (for example "Aciclovir , Oral", "Calcium Folinate , Injection", "Doxorubicin , Injection/Intravesical"). The class is therefore a catalogue of combinations rather than a generic therapeutic class.

• Revocation of earlier Determination: Section 3 expressly revokes the Determination made under subsection 99ACA(3) identified as PB 59 of 2007. That operation removes the earlier instrument from the operative administrative record and replaces it with this instrument for the period after commencement.

• Commencement mechanics: The instrument commences on registration on the Federal Register of Legislation (s 2). This ties the operative date to the register entry rather than to the signature date appearing on the instrument (19 September 2017), which may differ.

• Reference to external definitions: Section 5 includes a note that "terms used in this Determination have the same meaning as in the Act - see section 13 of the Legislation Act 2003," and gives examples including "pharmaceutical item," "listed component drug" and "manner of administration." The instrument therefore delegates definitional content to the National Health Act and the Legislation Act 2003.

These concepts combine to produce a narrow administrative outcome: a 12.5 percent administrative price reduction has been applied, by agreement under s 85AD, to the enumerated listed component drugs and manners of administration in the Schedule (s 6). The instrument does not set out operational or financial flows, enforcement penalties, or the negotiation process that produced the agreement; rather it records the result of that administrative process and the legal authority used.

The Determination identifies a defined set of listed component drugs and manners of administration and records that those listed items have taken a 12.5 percent administrative price reduction (s 6 and Schedule). The immediate legal effect in terms of who is directly identified by the instrument is therefore narrow: entities with interests in the listed component drugs in the specified manner of administration are the parties whose pricing positions are altered, at least on paper.

• Pharmaceutical suppliers and manufacturers: Any supplier whose product corresponds to a listed component drug and manner of administration in the Schedule is the primary commercial party to which the recorded price reduction will be relevant. The instrument itself does not name suppliers, but it identifies drugs by generic listed component designation (Schedule). Those suppliers will need to recognise that their listed component drug entries, when dispensed in the listed manner of administration, are the subject of the 12.5 percent administrative price reduction agreed under s 85AD.

• PBS administrators and pricing officers: Departmental officers, including those in Pricing and Policy Branch and Technology Assessment and Access Division, are the decision‑makers and record‑keepers shown here. The instrument was signed by the Assistant Secretary of that Branch, acting as delegate (instrument signature). Administrative teams responsible for updating schedules, pricing tables and register entries will be affected operationally because the Determination creates an obligation to reflect the 12.5 percent reduction for the enumerated items.

• Pharmacists and dispensing entities: The Determination does not itself speak to dispensing fees or patient co‑payments; it records a price reduction to the class of items. If pricing tables and reimbursement levels used by pharmacies for PBS dispensing are adjusted in response to the Determination, pharmacies will import that change to their internal pricing and claims processing systems. The instrument does not specify pass‑through rules or changes to patient copayments.

• Patients and prescribers: The instrument does not state any direct change to the listability, therapeutic indications, or clinical use of the drugs. It records an administrative price reduction applicable to the listed items. Any indirect effects on availability, patient cost or prescribing behaviour are not set out in the Determination itself and would depend on how pricing changes are reflected in PBS reimbursement schedules and commercial arrangements.

• Legal and compliance advisers: Because the instrument revokes an earlier Determination (PB 59 of 2007) (s 3), entities that were relying on the earlier Determination will need to note the revocation and confirm whether their products remain covered in the Schedule here. They will also need to consult the National Health Act, particularly section 85AD (referenced at s 5), and the Legislation Act 2003 (s 13) for definitive definitions, since this Determination delegates those definitional responsibilities.

• Parliament and oversight bodies: The Determination is an exercise of delegated authority under subsection 99ACA(3) (s 4). While the instrument itself records the administrative outcome, any scrutiny of the process, negotiation under s 85AD or the policy rationale would look to the Act and departmental records. The instrument provides the transparent legal record that the particular class has taken the specified administrative price reduction.

In short, the most directly affected parties are suppliers of the listed component drugs in the listed manner of administration and the administrative branches that maintain PBS pricing data. The Determination does not itself expand or contract therapeutic listings; it records an agreed non‑statutory price reduction and revokes a prior Determination.

This Determination is short and administrative. It does not create a broad set of duties or rights in express terms beyond the identification of the price reduction and the revocation of an earlier instrument. Nonetheless the instrument establishes or references a small set of legal positions and obligations that will be relevant to stakeholders.

• Obligation to recognise the Determination for administrative purposes: By operation of administrative practice, once the Determination has commenced on registration (s 2), departmental and PBS pricing systems will treat the specified listed component drugs and manners of administration as having taken a 12.5 percent administrative price reduction (s 6). The Determination does not itself state who must change which system, but the practical duty falls on those administering PBS listing and pricing to update records to reflect the instrument.

• Right to rely on the Determination as the administrative record: The instrument functions as the formal administrative record that the listed items have taken the identified reduction. Entities may rely on the Determination as evidence that the class has been subject to a 12.5 percent administrative price reduction agreed under s 85AD of the Act (s 5, s 6). That reliance is limited to the scope of the instrument and to the legal effect of delegated Determinations under subsection 99ACA(3).

• Revocation effect: The Determination revokes the earlier Determination PB 59 of 2007 (s 3). Parties who previously relied on PB 59 of 2007 must recognise that PB 59 is no longer in force as of this instrument’s commencement. The right to rely on PB 59 for ongoing administrative treatment of prices is removed by s 3. This creates an obligation for affected parties to transition their records and claims to align with PB 82 of 2017.

• Dependence on external legal definitions and processes: Section 5 explicitly ties definitions and the source of agreement for the administrative price reduction to other provisions: the meaning of "administrative price reduction" is defined with reference to s 85AD of the Act, and the note points to s 13 of the Legislation Act 2003 for other definitional terms. The practical duty for affected parties is therefore to consult those external statutory provisions to determine the precise legal meaning and mechanics. The Determination itself does not expand or override those definitions.

• No express enforcement or dispute procedure in this instrument: The Determination does not specify penalties, enforcement processes, or formal dispute resolution mechanisms. Any duties to comply with the 12.5 percent reduction, or rights to challenge or negotiate, must therefore derive from the underlying Act and the s 85AD agreement mechanism, neither of which is reproduced in the Determination. Parties seeking to assert or defend rights will need to turn to the National Health Act and the administrative arrangements referred to by s 85AD.

• Administrative signature and delegation: The instrument records that it was made by the Assistant Secretary, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, acting as delegate of the Minister for Health (instrument header and signature block). That shows the exercise of delegation and identifies the administrative office responsible for recording the Determination.

In summary, the Determination creates a limited administrative obligation to recognise and apply a 12.5 percent administrative price reduction to the Schedule items, revokes a prior Determination, and requires interested parties to consult the underlying statutory provisions for definitional and procedural content. The instrument itself contains no separate criminal or civil penalty framework, nor does it specify operational rights such as reimbursement adjustments or dispute procedures.

The Determination contains no express penalties, sanctions or enforcement provisions. Its operative content is declaratory and administrative: it revokes an earlier Determination and records that a specified class of pharmaceutical items "have taken a 12.5% administrative price reduction" (s 3, s 6). There is no clause in the text that prescribes criminal offences, civil penalties, pecuniary fines, or administrative sanctions for non‑compliance with the Determination itself.

Relevant observations drawn from the instrument are as follows.

• No express enforcement mechanism: The Determination neither establishes an enforcement agency nor prescribes a compliance audit or penalty regime within its text. It is an instrument under subsection 99ACA(3) of the National Health Act 1953 (s 4), and any enforcement mechanisms that apply to pricing, agreements under s 85AD, or PBS administration would stem from the National Health Act or other statutory or administrative instruments, not from this Determination itself. The Determination directs readers to s 85AD by definition (s 5), but does not reproduce or implement enforcement provisions from that section.

• Administrative effect is declaratory: The instrument functions as a formal record that the class in the Schedule has taken an administrative price reduction. As such, the immediate administrative obligation is to reflect that reduction in PBS pricing and administrative documentation. Ensuring that public registers, PBS schedules and pricing datasets are updated is an administrative task, not one tied to a penalty stated in this instrument.

• Revocation does not itself create penalties: The revocation clause (s 3) removes the earlier Determination PB 59 of 2007. The instrument does not create transitional penalties for failing to replace or update systems. The absence of explicit transitional enforcement measures means any compliance obligations arising from the revocation will be managed through administrative processes under the National Health Act and departmental practice.

• Dispute or challenge pathways are not set out here: The Determination does not specify how parties may contest or seek review of the administrative price reduction. Any rights of review, appeal or judicial challenge must therefore be located in the National Health Act or in administrative law remedies available to affected parties. The instrument’s silence on remedies means stakeholders must consult the underlying Act and broader administrative law frameworks to identify enforcement or review options.

• Practical enforcement will be operational: In practice, enforcement of price reductions in PBS contexts typically occurs through administrative management of reimbursement schedules, claims processing systems and contractual negotiation outcomes. This Determination’s immediate enforcement implication is that administrative systems that rely on authoritative Determinations should be updated to record the 12.5 percent reduction for the specified items, but the instrument itself does not prescribe sanctions for failing to do so.

Legal advisers and compliance teams should therefore rely on the National Health Act and the s 85AD agreement mechanisms for any binding enforcement or dispute resolution constructs, since PB 82 of 2017 is limited to recording the class and the agreed percentage reduction.

The Determination deliberately references and relies on provisions in other primary instruments rather than repeating them. The text establishes a web of interaction points that users must consult to understand the full legal and procedural consequences. The instrument itself identifies the following connections.

• National Health Act 1953: The Determination is made under subsection 99ACA(3) of the National Health Act 1953 (s 4) and defines "administrative price reduction" by reference to an agreement under section 85AD of that Act (s 5). Therefore, the procedural basis for agreeing the administrative price reduction, any rights attached to such an agreement, and any statutory constraints on the power to make Determinations under subsection 99ACA(3) are matters that must be resolved by reference to the National Health Act. The Determination does not reproduce those statutory provisions, it relies on them.

• Legislation Act 2003, section 13: Section 5 contains a note that terms used in the Determination have the same meaning as in the Act and refers explicitly to section 13 of the Legislation Act 2003. This establishes that defined terms such as "pharmaceutical item," "listed component drug," and "manner of administration" are to be read as they are defined in the National Health Act or as clarified by the Legislation Act 2003’s guidance on statutory interpretation and references. The Determination therefore functions as an instrument that must be read with the definitional framework provided by those primary statutes.

• Previous Determination (PB 59 of 2007): The text revokes the Determination under subsection 99ACA(3) identified as PB 59 of 2007 (s 3). That revocation severs any continuing administrative effect of PB 59 of 2007 and replaces it, for the relevant items, with PB 82 of 2017. The legal relationship between PB 82 of 2017 and any other subordinate instruments, contractual arrangements or administrative records that referenced PB 59 of 2007 will need to be checked for continuity, conflict or adjustment.

• Section 85AD of the National Health Act: The defined term "administrative price reduction" expressly ties the Determination’s operative content to agreements under s 85AD. The interaction here is substantive since the existence, validity and content of the price reduction depend on an agreement under s 85AD. Determination PB 82 records the outcome of that agreement; any legal questions about the authority to agree a non‑statutory reduction, the parties capable of entering the agreement, or the negotiation process will be governed by section 85AD and any related provisions in the National Health Act.

• Administrative law and Federal Register practice: The instrument’s commencement is tied to registration on the Federal Register of Legislation (s 2). That links the Determination to statutory administrative publication requirements, and to any legal consequences that flow from the public registration of delegated instruments. The Determination will therefore be read and given effect in the context of administrative law principles that govern the validity, publication and operation of delegated instruments.

Because PB 82 of 2017 is a brief, specialised instrument, all substantive legal rights, obligations and procedural mechanisms relevant to the 12.5 percent reduction are found in the primary Act and associated administrative frameworks. The Determination records the applied outcome, revokes an earlier instrument, and cross‑references the statutory architecture rather than incorporating it.

The Determination contains its own minimal amendment history and procedural metadata. The text makes the following points relevant to a user reconstructing the instrument’s lifecycle.

• Instrument identification and date: The Determination is identified as PB 82 of 2017 and is dated 19 September 2017 in the signature block (instrument header and signature). The instrument’s formal title is National Health (Pharmaceutical Benefits Scheme‑ class of pharmaceutical items - Subsection 99ACA(3) Determination 2017 (s 1(1)).

• Commencement mechanics: Section 2 specifies that the Determination commences on the date of registration on the Federal Register of Legislation. Therefore, the instrument’s practical commencement date will be the register entry date rather than the signature date. That distinction is relevant when reconstructing timelines and assessing the period of operative effect.

• Revocation of prior instrument: Section 3 provides the only explicit amendment action recorded in the Determination: "The Determination under subsection 99ACA(3) of the National Health Act 1953 (PB 59 of 2007) is revoked." That establishes that PB 59 of 2007 no longer has force as of the commencement of PB 82 of 2017. The Determination does not, however, record any other amendments or partial continuations of earlier measures.

• No recorded subsequent amendments within the instrument: The text of PB 82 of 2017 contains no clauses authorising further amendment, nor does it include a schedule of amendments or transitional provisions beyond the revocation of PB 59 of 2007. If future instruments modify or replace PB 82 of 2017, those changes would appear in subsequent Determinations or statutory instruments; they are not shown here.

• Delegation and authorisation metadata: The instrument identifies the office holder who made it , LISA LA RANCE, Assistant Secretary, Pricing and Policy Branch, Technology Assessment and Access Division , and expressly notes the delegate status of the officer acting for the Minister for Health. That record of delegation is part of the instrument’s administrative provenance and is relevant for any review of the decision‑making chain.

For tracing amendment history beyond these entries, users must consult the Federal Register of Legislation for subsequent Determinations, the National Health Act for related statutory changes, and departmental records concerning agreements under s 85AD and any negotiation transcripts. The Determination itself contains only a single revocation and does not include an ongoing amendment log.

The Determination text contains no references to litigation, court proceedings, decisions, or appeals. There is no recorded case law cited within the instrument, nor are there footnotes or references to judicial determination of the legal questions connected to the instrument. The document is a short administrative record and does not incorporate or summarise any litigation.

From the content of the Determination itself, the following observations follow.

• No internal reference to judicial review or challenges: The instrument does not set out any information regarding whether the administrative price reduction agreement under section 85AD, or the decision to record the reduction via subsection 99ACA(3), has been litigated or is subject to litigation. The Determination is silent on any disputes.

• Revocation and litigation: The revocation of PB 59 of 2007 is recorded at s 3. The Determination does not indicate whether that revocation followed litigation, settlement, policy change, or routine administrative update. Any litigation history that might relate to PB 59 of 2007 or to pricing arrangements under s 85AD would not be disclosed in this instrument.

• Implication for researchers and litigators: Because the Determination makes no mention of litigation, a legal researcher seeking to determine whether any disputes arose over the administrative price reduction or the delegation would need to search external judicial records, administrative law filings, or departmental correspondence. The Determination itself furnishes no litigation trail.

• No statutory provision in the instrument by which to read litigation outcomes into the text: Absent reproducing the underlying sections of the National Health Act, the Determination does not memorialise any adverse judicial findings, orders, injunctions, or formal challenges. Any litigation that might affect the validity or operation of the price reduction would be traceable only through external records.

In short, PB 82 of 2017 contains no in‑instrument litigation history or references. Interested parties must consult external sources, such as court records or departmental archives, to determine whether any disputes or judicial review have arisen in relation to this Determination or the underlying s 85AD agreements it records.

The Determination is short and seemingly straightforward, but several practical and legal "gotchas" arise from the instrument’s design, cross‑references and drafting choices. These are matters that can create confusion, operational risk or compliance gaps if not expressly checked against the National Health Act and administrative practice.

• Commencement is the registration date, not the signature date (s 2): The instrument is dated 19 September 2017 at signature, but s 2 makes commencement the date of registration on the Federal Register of Legislation. Parties relying on the instrument must confirm the register date to establish when the 12.5 percent reduction became operative for administrative purposes. Failure to do so could create disputes over which pricing regime applied on particular claim dates.

• "Administrative price reduction" is defined as non‑statutory and depends on s 85AD (s 5): The Determination’s definition characterises the reduction as a non‑statutory reduction "agreed under section 85AD." That language means the legal basis, negotiation participants, and enforceability of the reduction are governed by section 85AD and not by this instrument. Users must therefore consult s 85AD to understand whether the reduction is bilateral, multilateral, negotiable, revocable, conditional, or otherwise constrained. Treating the determination as self‑contained on price mechanics would be an error.

• Scope depends on exact pairing of listed component drug and manner of administration (s 6 and Schedule): The Schedule identifies items by listed component drug and manner of administration. The Determination applies to each listed pairing. If a product is dispensed in a manner of administration that does not match the Schedule entry, or if a drug is referred to by a different component name, there is risk of misclassification. For example, some drugs are listed twice with different manners (e.g., Dolasetron , Injection and Dolasetron , Oral). Accurately matching the product to the Schedule entry is essential to determine whether the 12.5 percent reduction applies.

• Duplicate and multi‑manner entries in the Schedule require granular matching: Several listed component drugs are recorded in both oral and injection forms (for example Ondansetron and Granisetron). Some entries specify combined administration forms (e.g., Doxorubicin , Injection/Intravesical). Administrative systems and claims processors must recognise those specific manner descriptors, or claims may be misclassified.

• Revocation of PB 59 of 2007 may have transitional implications (s 3): The Determination revokes the earlier PB 59 of 2007. Entities that adjusted systems, contracts or pricing models under PB 59 must check for unintended gaps or overlapped obligations following revocation. The Determination does not provide transitional rules nor instruct how to treat claims spanning the revocation/commencement period.

• Definitions are not self‑contained: The note at s 5 cross‑references section 13 of the Legislation Act 2003 for meaning of terms used in the Determination, including "pharmaceutical item," "listed component drug," and "manner of administration." A common mistake would be to assume colloquial meanings; those statutory definitions may be narrower or different than ordinary language, and the Determination’s effect depends on those statutory definitions.

• The Determination is declaratory about the existence of the reduction; it does not detail operational adjustment of reimbursement or co‑payment levels: Stakeholders may assume that the 12.5 percent reduction automatically changes patient copayments or pharmacy remuneration. That is not stated here. The Determination records the administrative price reduction but does not itself describe how it is implemented through PBS reimbursement schedules or claims processing. Operational implementation is likely handled elsewhere.

• No express dispute or appeal avenue recorded in the instrument: The Determination does not specify how an affected party might contest the application, scope or validity of the 12.5 percent reduction. Any recourse would rest in the underlying Act and general administrative law paths. Relying solely on the Determination for dispute procedures would be an error.

• Narrow scope means omissions matter: Because the instrument lists specific listed component drugs and manners of administration, any item not included is not covered by the 12.5 percent reduction according to the instrument’s text. Errors of omission in the Schedule would not be rectified by this Determination; corrections require a further instrument or administrative action.

Careful operational checks against the National Health Act definitions, the s 85AD agreement record, PBS pricing tables and the Federal Register commencement entry are therefore necessary to avoid misapplication or incorrect accounting of the reduction.

Compliance with the Determination requires a small set of concrete steps because the instrument is primarily an administrative record. The following checklist sets out actions for suppliers, PBS administrators, pharmacists, legal advisers and compliance teams to ensure accurate application of the Determination’s effect.

1. Confirm the commencement date on the Federal Register of Legislation (s 2).

   • The instrument’s operative date is the date of registration on the Federal Register of Legislation. Obtain the exact register entry date and use that date to identify the point from which administrative pricing records should reflect the 12.5 percent reduction.

2. Map products to Schedule entries (s 6 and Schedule).

   • For each product you supply or dispense, confirm whether the product’s listed component drug and manner of administration precisely match an entry in the Schedule. Pay special attention to entries that appear in more than one manner of administration (for example, oral and injection forms are listed separately for numerous drugs). Accurate mapping determines whether the 12.5 percent reduction applies.

3. Consult section 85AD of the National Health Act 1953 and relevant PBS guidance (s 5).

   • The Determination defines "administrative price reduction" as a non‑statutory price reduction agreed under s 85AD. To understand the legal basis, negotiable terms, duration, revocability, and any conditions attaching to the reduction, consult the full text of s 85AD and any related ministerial or departmental guidance. The Determination itself does not set procedural rules.

4. Update PBS pricing and claims processing systems.

   • If you are an administrator or a pharmacy, ensure that pricing tables, claims submission systems and reimbursement calculations incorporate the 12.5 percent administrative price reduction for the relevant items from the confirmed commencement date. Verify that claims for manners of administration that are multi‑listed are processed against the correct Schedule entry.

5. Review contracts and supply agreements for pricing implications.

   • Suppliers should review commercial agreements with wholesalers, pharmacies and payers to determine whether the 12.5 percent administrative price reduction requires contract renegotiation, price adjustments, or operational changes to invoicing and settlement systems. The Determination is the administrative record that the reduction exists; its contractual treatment depends on existing agreements and on s 85AD outcomes.

6. Note revocation of PB 59 of 2007 and assess transitional issues (s 3).

   • Organisations that implemented systems under PB 59 of 2007 must ensure there are no gaps or conflicting administrative records following revocation. Reconcile historical data and claims spanning the revocation and new commencement dates, and adjust internal documentation to refer to PB 82 of 2017 where appropriate.

7. Document and retain evidence of administrative updates.

   • For audit and compliance purposes, record the Federal Register commencement date, system change logs, mapping tables linking your products to Schedule entries, and the source documents used (the Determination, s 85AD guidance, PBS tables). The Determination is a short record; link it to the more detailed materials used to operationalise the 12.5 percent reduction.

8. Seek legal advice for disputes or interpretation questions.

   • The Determination does not set out enforcement or dispute processes. If there is disagreement about whether an item falls within the Schedule, the duration or validity of the s 85AD agreement, or whether the reduction has been properly applied, seek legal advice and consider administrative law remedies or consult the National Health Act provisions.

9. Communicate changes to stakeholders.

   • Inform affected parties, including wholesalers, pharmacies and clinical procurement teams, about the mapped items, the confirmed commencement date, and any system or billing implications. Because the Determination does not prescribe changes to patient co‑payments, clarify how, if at all, the reduction is expected to interact with patient billing under current PBS rules.

10. Monitor for further Determinations or amendments.

• Because PB 82 of 2017 is a delegated instrument and it revoked a previous Determination, there is potential for further administrative Determinations. Monitor the Federal Register for subsequent instruments that may amend, replace or clarify the operation of administrative price reductions for PBS items.

By following these steps and anchoring compliance work to the primary statute references identified in the Determination (notably s 85AD and the definitions in the National Health Act and Legislation Act 2003), affected parties can ensure they reflect the 12.5 percent administrative price reduction recorded in PB 82 of 2017 and can identify where further statutory or administrative guidance is required.